IIPMP A.I CyberSecurity Scoring
01/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. in 2026.
No incidents recorded for IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. in 2026.
No incidents recorded for IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. in 2026.
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Latest updates, reports, and threat intel affecting the global network.
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when a `ClientPasswordReset` record already exists for a client (from a previous unexpired reset request), subsequent calls to the `reset_password` guest API endpoint reuse the existing token instead of generating a new one. The 15-minute validity window is anchored to the first request's `created_at` timestamp, not the time of the most recent email. An attacker who obtained the original reset link remains able to use it even after the victim requests a new reset, because the original token is never invalidated or rotated. Version 0.8.0 patches the issue. Some workarounds are available. Configure a reverse proxy (e.g., Nginx, Apache, Cloudflare) to apply per-IP rate limiting to the `/client/reset-password` endpoint to minimize the window of opportunity, and/or manually clear expired `client_password_reset` records from the database after a client reports a suspected compromise.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow a low-privileged staff account to grant arbitrary module permissions to itself through the admin API, resulting in persistent privilege escalation. A staff user that only has `staff.create_and_edit_staff` can call `/api/admin/staff/permissions_update` targeting their own account and write any permission structure, bypassing the intended role-based access control boundary. Version 0.8.0 patches the issue. Some workarounds are available. Restrict the `staff.create_and_edit_staff` permission to only highly trusted staff members and/or use a reverse proxy or WAF to restrict access to `/api/admin/staff/permissions_update` to specific trusted roles.
FOSSBilling is a free, open-source billing and client management system. Versions 0.5.3 through 0.7.2 allow authenticated clients to both read and reset API key service secrets for orders that are no longer in an `active` state (e.g., `suspended`, `canceled`). The root cause is missing order-state validation in two client API endpoints, despite an `isActive()` helper already existing in the `Serviceapikey` module and the frontend UI correctly gating access on `order.status == 'active'`. Version 0.8.0 contains a fix. Some workarounds are available. If the `Serviceapikey` module is not needed, uninstall it to remove the affected endpoints. One may also use a reverse proxy or WAF to restrict access to `/api/client/order/service` and `/api/client/serviceapikey/reset` based on application-level order-state logic.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow low-privileged staff accounts to perform unauthorized actions via admin API endpoints. The root cause is a combination of the `can_always_access` module flag (which grants all staff access to certain modules) and insufficient permission checks or unsafe parameter handling on individual endpoints. Version 0.8.0 contains a fix. Some workarounds are available. Restrict staff accounts to only those who need access to sensitive settings and/or use a reverse proxy or WAF to restrict access to the affected endpoints to trusted IP addresses or higher-privilege roles.
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when the "Require Email Confirmation" setting is enabled, a logged-in client with an unverified email address (`email_approved = 0`) can access all client-area pages (e.g. `/client/balance`, `/client/order/list`, `/client/invoice`) and read real account data, including wallet balances and transaction history. The API-side enforcement correctly restricts unverified clients to only profile-related endpoints, but the page-side enforcement is overly permissive, allowing any request whose path starts with `/client`. Version 0.8.0 contains a fix. No known workarounds that don't involve modifying the source code are available.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.